ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1225

Fibromyalgia as a Potential Initial Presentation for Autoimmune Conditions

Qi Wang1, Pratibha Chaudhary2, Yu Chang3 and Megha Garg4, 1Unity Hospital/Rochester Regional Health, Rochester, NY, 2Rochester General Hospital, Rochester, NY, 3National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), 4Rochester Regional Health, Rochester, NY

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, fibromyalgia

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Pain in Rheumatic Disease Including Fibromyalgia Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Fibromyalgia is a non-autoimmune disease with widespread pain, severe fatigue, and sleep problems. There are limited studies examining the association between fibromyalgia and autoimmune conditions, and so far, there is no evidence showing that fibromyalgia could be a potential initial presentation for autoimmune diseases. We aim to investigate the potential association between fibromyalgia and autoimmune conditions.

Methods: We conducted a retrospective, propensity score matched study using the TriNetX database, a network comprising deidentified data across the world. We included 14,309 patients who were diagnosed with fibromyalgia between November 1, 2018, and January 1, 2019, from 118 health institutions worldwide with no existing diagnosis of autoimmune conditions before or up to 1 month after the diagnosis of fibromyalgia, comparing them with a matched control group without fibromyalgia diagnosis. The primary outcomes were development of autoimmune conditions and number of ambulatory visits between 1 month and 5 years after the diagnosis of fibromyalgia. Propensity score was matched by incorporating variables including age, gender, race, smoking history, family of arthritis and other connective tissue diseases, body mass index (BMI).

Results: The median age was 57 ± 15 years, with 91% females, and 84% white individuals in both groups. In our risk assessment, 320 (2.2%) out of 14,309 patients diagnosed with fibromyalgia developed rheumatoid arthritis (RA) in the next 5 years compared to 76 (0.5%) in the control group without fibromyalgia (odds ratio (OR), 4.28, 95% confidence interval (CI), [3.33, 5.51]). In Kaplan – Meier survival analysis, fibromyalgia was found to be associated with higher risk of developing RA (hazard ratio (HR), 4.10, 95% CI, [3.20, 5.27], p< 0.0001). There were 195 (1.4%) patients developing systemic lupus erythematous (SLE) in fibromyalgia group compared with 40 (0.3%) patients in control group (OR, 4.93, 95% CI, [3.50, 6.93]). In Kaplan – Meier analysis, fibromyalgia was associated with higher risk of SLE (HR, 4.74, 95% CI, [3.37, 6.66]). Similarly, fibromyalgia was found to be associated with higher incidence of Sjogren’s syndrome, psoriatic arthritis, and inflammatory arthritis (table 1). Patients with fibromyalgia also tend to have more ambulatory visits in the next 5 years compared with control group (76 vs 45, p < 0.0001).

Conclusion: Overall, fibromyalgia is associated with higher risk of autoimmune conditions and could be a potential initial manifestation of autoimmune conditions. As providers, we should be alarmed if our patients start to show signs of arthralgia or other signs of autoimmune disorders instead of attributing everything to fibromyalgia. Further studies are needed to evaluate potential predictors for future development of autoimmune conditions in fibromyalgia patients.

Supporting image 1

Table1: Comparison of Autoimmune Condition Incidence in Patients with and without Fibromyalgia


Disclosures: Q. Wang: None; P. Chaudhary: None; Y. Chang: None; M. Garg: None.

To cite this abstract in AMA style:

Wang Q, Chaudhary P, Chang Y, Garg M. Fibromyalgia as a Potential Initial Presentation for Autoimmune Conditions [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/fibromyalgia-as-a-potential-initial-presentation-for-autoimmune-conditions/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fibromyalgia-as-a-potential-initial-presentation-for-autoimmune-conditions/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology